[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649806":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":62,"collaborators":64,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":24,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":93,"whyStopped":24,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Olivia Newton-John Cancer Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm 1 (TA1) (recurrent GBM)","EXPERIMENTAL","Dose Escalation Study drug CT-179 at multiple dose levels",[13],"Drug: CT-179",{"label":15,"type":10,"description":16,"interventionNames":17},"Treatment Arm 2 (TA2) (newly diagnosed MGMT-unmethylated GBM)","Dose Escalation Study drug CT-179 at two dose levels",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","CT-179","Daily administration of CT-179",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Alexandra Romano","CONTACT","+61 3 9496 3573","opal@onjcri.org.au",[32,49],{"facility":33,"status":24,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Royal Brisbane and Women's Hospital","Herston","Queensland","4006","Australia","AU",{"type":40,"coordinates":41},"Point",[42,43],153.01852,-27.44453,{"lat":43,"lon":42},[46],{"name":47,"role":48,"phone":24,"phoneExt":24,"email":24},"Prof Zarnie Lwin","PRINCIPAL_INVESTIGATOR",{"facility":50,"status":24,"city":51,"state":52,"zip":53,"country":37,"countryCode":38,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Austin Health","Heidelberg","Victoria","3084",{"type":40,"coordinates":55},[56,57],145.06667,-37.75,{"lat":57,"lon":56},[60],{"name":61,"role":48,"phone":24,"phoneExt":24,"email":24},"Prof Hui Gan",{"type":63,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[65],{"name":66,"class":67},"Curtana Pharmaceuticals, Inc.","INDUSTRY","100649806","phase-1-olig2-inhibitor-ct-179-for-recurrent-and-newly-diagnosed-glioblastoma-100649806",false,"NCT07739017","OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma","A Phase 1, Two-Part, Accelerated Dose Titration Trial of CT-179 as Monotherapy in the Treatment of Recurrent Glioblastoma and in Combination With Radiation Therapy in the Treatment of Newly Diagnosed MGMT-Unmethylated Glioblastoma","OPAL","Inclusion Criteria:\n\n* Male or female aged ≥ 18 years at the time of signing informed consent\n* Supratentorial, histologically confirmed diagnosis of primary GBM that meets the current diagnostic classification: 2021 WHO Classification of Tumors of the Central Nervous System\n* KPS score ≥ 70\n* Adequate organ function\n* Contraception during study participation, as applicable\n* Able to swallow tablets\n\nExclusion Criteria:\n\n* Treatment with an investigational agent within the last 30 days excluding 5- aminolevulinic acid (5-ALA)\n* Placement of Gliadel wafers or similar local therapy at time of surgery\n* Receive bevacizumab\n* Evidence of intracranial or intra-tumoral hemorrhage\n* Significant concomitant disorder or serious intercurrent illness\n* History of prior malignancy, except adequately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, or disease-free for more than 5 years\n* Treatment for HIV, hepatitis B, or hepatitis C\n* Any gastrointestinal disorder that could result in reduced absorption of CT-179\n* Any psychiatric illness or social situation that would limit compliance with study requirements\n* Dose of dexamethasone higher than 4 mg\u002Fday within 1 week of the first dose of study medication","ALL","18 Years","75 Years",{"count":80,"type":81},54,"ESTIMATED","INTERVENTIONAL",[84],"PHASE1","This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in patients with recurrent glioblastoma and newly diagnosed MGMT-unmethylated glioblastoma who are eligible to receive radiation therapy following surgery, and to establish the recommended Phase 2 dose.",[87,88],"Recurrent Glioblastoma","Newly Diagnosed MGMT Unmethylated Glioblastoma",[90,91,92],"Glioblastoma","Brain Tumour","OLIG2","NOT_YET_RECRUITING","2026-07-27",{"date":96,"type":97},"2026-07-31","ACTUAL",{"date":99,"type":81},"2026-12",{"date":101,"type":81},"2028-09",{"name":5,"class":6},2]